Home > Result Summaries: Compounds > fosamprenavir > Result Summary for 111945_4

Result Summary for 111945_4

Result Summary

Protocol ID:	111945_4
Clinical Study ID:	WWE111945
Official Title:	Studies using DAD - HIV and Hepatitis Coinfection Initiative
Phase:	N/A
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	Lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Weber R, Sabin C, P Reiss P, et al. Hepatitis virus co-infections and risk of diabetes mellitus and myocardial infarction in HIV-infected persons: The D:A:D Study. Poster 1082. 15th Conference on Retroviruses and Opportunistic Infections. February 3-6. 2008. Boston, Massachusetts. Link: http://www.retroconference.org/2008/Abstracts/31672.htm Weber R, Friis- Møller N , Sabin C, et al. Liver-related deaths among HIV-infected persons: Data from the D:A:D Study. Poster PE18.4/7. 10th European AIDS Conference (EACS). November 17-20, 2005, Dubin, Ireland The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-Related deaths in persons infected with the human immunodeficiency virus. The D:A:D Study. Arch Intern Med. 2006;166:1632-1641 Weber R, Sabin C, Friis-Møller N, et al. Exposure to ART and the Risk of Liver-related Death: Is there an Association? Results from the D:A:D Study. Poster 770. 13th Conference on Retroviruses and Opportunistic Infections. February 5-8. 2006. Denver, Colorado. Link: http://www.retroconference.org/2006/Abstracts/27396.HTM Puoti M, Cozzi-Lepri A, Arici C, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBs-Ag- and HIV-positive individuals: results from an inter-cohort analysis. Antiviral Therapy 2006;11:567-574